RBC Capital Reiterates Sector Perform on BioCryst Pharma, Maintains $10 Price Target
RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Sector Perform and maintains $10 price target.
JMP Securities Reiterates Market Outperform on Vacasa, Maintains $3 Price Target
JMP Securities analyst Eric Ross reiterates Vacasa (NASDAQ:VCSA) with a Market Outperform and maintains $3 price target.
RBC Capital Maintains Sector Perform on AcuityAds Holdings, Raises Price Target to C$3.5
RBC Capital analyst Drew McReynolds maintains AcuityAds Holdings (TSX:AT) with a Sector Perform and raises the price target from C$3 to C$3.5.
JMP Securities Reiterates Market Outperform on Inspired Entertainment, Maintains $18 Price Target
JMP Securities analyst Jordan Bender reiterates Inspired Entertainment (NASDAQ:INSE) with a Market Outperform and maintains $18 price target.
JMP Securities Reiterates Market Outperform on Booking Holdings, Maintains $2750 Price Target
JMP Securities analyst Nicholas Jones reiterates Booking Holdings (NASDAQ:BKNG) with a Market Outperform and maintains $2750 price target.
Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $26
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $24 to $26.
BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1025
BMO Capital analyst Evan Kurtz maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $1001 to $1025.
Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $33
Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $28 to $33.
Raymond James Maintains Strong Buy on Globe Life, Lowers Price Target to $138
Raymond James analyst Wilma Burdis maintains Globe Life (NYSE:GL) with a Strong Buy and lowers the price target from $141 to $138.
Janney Montgomery Scott Downgrades Hancock Whitney to Neutral, Announces $44.5 Price Target
Janney Montgomery Scott analyst Christopher Marinac downgrades Hancock Whitney (NASDAQ:HWC) from Buy to Neutral and announces $44.5 price target.